Quanterix Corporation (QTRX)
NASDAQ:QTRX
Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$3.50
-$0.25(-2.12%)
At close: 4:00 PM EST
$3.50
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.40 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$166.28M
Enterprise Value$143.30M
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$35.34M
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 10, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding47,105,980
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue0.99
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$4.00Price Target Upside14.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.48
Revenue Forecast (FY)$169.93M
Bulls Say, Bears Say
Bulls Say
Installed Base & Market LeadershipA >2,300 instrument installed base and category leadership in ultrasensitive assays create durable competitive moats. Instruments entrench customers, drive recurring consumables and services revenue, and raise switching costs across neurology, oncology and translational research workflows.
High Gross Margins & Consumables Pull‑ThroughSustained non‑GAAP gross margins above 49% indicate strong unit economics on consumables and assays. Because consumables are recurring and tied to installed instruments, this margin profile supports durable gross profitability and long‑term margin sustainability as installed base monetization continues.
Healthy Cash Position & Realized SynergiesA ~ $102.6M cash balance, expectation to end 2026 near $100M with no debt, and delivered cost synergies materially improve financial flexibility. Realized $85M annualized synergies and solid cash reduce refinancing risk and support management's path toward H2 2026 cash‑flow breakeven.
Bears Say
Persistent Cash Burn & Large Net LossesOperating and free cash flow remain deeply negative on a TTM basis, reflecting sustained cash burn. Continued negative cash generation increases reliance on external financing or drastic cost reduction if revenue recovery lags, threatening the durability of the breakeven timeline and strategic investments.
Organic Revenue Declines & Weak Instrument DemandMaterial organic declines across core product lines and soft instrument placements indicate structural end‑market weakness. Lower academic and pharma demand (pharma down 33%) reduces future high‑margin consumables pull‑through and impairs the company's ability to grow sustainably from its installed base.
Profitability Deterioration & Compressed MarginsSeverely negative operating and net margins alongside widening losses signal deep profitability challenges. Even with strong non‑GAAP gross margins, heavy operating expenses, acquisition‑related charges and declining equity since 2021 limit financial resilience and prolong the time required to generate positive shareholder returns.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.40 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $166.28M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Aug 10, 2026 which is in 66 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on May 06, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.143.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.4.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,105,980 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went down -16.413%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (14.29% Upside)
$4.00 (14.29% Upside)
Hedge Fund Trend
Increased
By 768.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.9%
Last 30 Days ▼ 5.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
-35.17%
Trailing 12-Months
Asset Growth
-7.53%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. It offers HD-X instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids. The company also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assay kits and other consumables such as reagents. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct sales force, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
QTRX Company Deck
QTRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed encouraging operational and financial progress—an increase in reported revenue, strong non-GAAP gross margins above 50%, delivery of $85M in synergies, a healthy cash balance (~$102.6M), and clear strategic investments in commercial capabilities and diagnostics (HD-X IVD push, Tempus partnership). Offsetting these positives are material organic revenue declines (Simoa -21%, spatial -26%), a 33% drop in pharma revenue, softer-than-expected instrumentation sales, and notable one-time acquisition-related charges. Management maintained full-year guidance and outlined concrete steps to drive H2 improvement and cash-flow breakeven, but near-term execution and end-market recovery remain key risks.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(14.29% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
7.05% Insiders
17.87% Mutual Funds
36.89% Other Institutional Investors
27.88% Public Companies and
Individual Investors